Health Canada has approved Lemtrada (alemtuzumab) from Genzyme, a Sanofi company, for the management of adult patients with relapsing remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies. Lemtrada’s has a clinical development program that involved nearly 1,500 patients and 5,400 patient-years of follow-up. The Canadian approval was based on data from th...